Synthesis, antibacterial, antifungal and anti-HIV activities of norfloxacin Mannich bases

European Journal of Medicinal Chemistry

Volumn 35, Issue 2, 2000, Pages 249-255

  Pandeya, Surendra N ^a   Sriram, Dhamrajan ^a   Nath, Gopal ^b   De Clercq, Erik ^c  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antimicrobial; Isatin; Mannich bases; Norfloxacin

Indexed keywords

1 ETHYL 6 FLUORO 1,4 DIHYDRO 4 OXO 7 [[N (3' SULFADIAZINIMINO 1' ISATINYL)METHYL]N PIPERAZINYL] 3 QUINOLINECARBOXYLIC ACID; 1 ETHYL 6 FLUORO 1,4 DIHYDRO 4 OXO 7 [[N (3' SULFADOXIMINO 1' ISATINYL)METHYL]N PIPERAZINYL] 3 QUINOLINECARBOXYLIC ACID; 1 ETHYL 6 FLUORO 1,4 DIHYDRO 4 OXO 7 [[N [3' (4' AMINO 5' TRIMETHOXYBENZYLPYRIMIDIN 2' YL)IMINO 1' ISATINYL]METHYL]N PIPERAZINYL] 3 QUINOLINECARBOXYLIC ACID; 1 ETHYL 6 FLUORO 1,4 DIHYDRO 4 OXO 7 [[N [5' BROMO 3' (4' AMINO 5' TRIMETHOXYBENZYLPYRIMIDIN 2' YL)IMINO 1' ISATINYL]METHYL]N PIPERAZINYL] 3 QUINOLINECARBOXYLIC ACID; CLOTRIMAZOLE; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFADIAZINE; SULFADOXINE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LD 50; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOSIS; NONHUMAN; REACTION ANALYSIS;

EID: 0034022016     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(00)00125-2     Document Type: Article

References (17)

1. Koga H., Itoh A., Murayama S., Suzue S., Irikura T. J. Med. Chem. 37:1980;1358-1363.
2. Daisley R.W., Shah V.K. J. Pharm. Sci. 73:1984;407-408.
3. Gupta R.P., Narayan N.L. Pharm. Acta Helv. 72:1997;43-46.
4. Piscopo E., Diurno M.V., Gogliardi R., Cucciniello M., Veneruso G. Boll. Soc. Ital. Biol. Sper. 63:1987;827-830.
5. Teitz Y., Ronen D., Vansover A., Stematsky T., Riggs J.L. Antivir. Res. 24:1994;305-314.
6. Pandeya S.N., Yogeeswari P., Sriram D., De Clercq E., Pannecouque C., Witvrouw M. Chemotherapy. 45:1999;192-196.
7. Teitz Y., Barko N., Abramoff M., Ronen D. Chemotherapy. 40:1994;195-200.
8. Kashiwase H., Momota K., Ohmine T., Komai T., Kimura T., Katsube T., et al. Chemotherapy. 45:1999;48-55.
9. Pandeya S.N., Usha L., Pandey A., Bajpai S.K. Indian J. Het. Chem. 6:1997;313-316.
10. Pandeya S.N., Yogeeswari P., Sriram D., Nath G. Boll. Chim. Farm. 137:1998;321-324.
11. Pandeya S.N., Sriram D. Acta Pharm. Turc. 40:1998;33-37.
12. Crumplin G.C., Midgley J.M., Smith J.T. Top. Antibiot. Chem. 3:1979;9-38.
13. Barry A. Procedures and theoretical considerations for testing antimicrobial agents in agar media. Corian. Antibiotics in Laboratory Medicine. 1991;1-16 Willam and Wilkins, Baltimore.
14. Popovic M., Sarngadhara M.G., Read E., Gallo R.C. Science. 224:1984;497-500.
15. Pauwels R., De Clercq E., Desmytes J., Balzarini J., Gouban P., Herdewijn P., Vanderhaughe H., Vandeputte H. J. Virol. Methods. 16:1987;171-173.
16. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmytes J., De Clercq E. J. Virol. Methods. 20:1987;309-322.
17. Weil C.S. J. Biometric. Soc. 8:1952;249.